Related Experiment Video
Updated: Oct 26, 2026

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
Centanafadine: First Approval
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Abstract:
Centanafadine (SIMTRIYO®) is a first-in-class, sustained-release norepinephrine, dopamine and serotonin reuptake inhibitor and central nervous system stimulant developed by Otsuka Pharmaceutical for the treatment of attention-deficit hyperactivity disorder (ADHD). Centanafadine recently received approval in the USA for the treatment of ADHD in adult patients and paediatric patients aged ≥ 6 years weighing ≥ 20 kg. This article summarizes the milestones in the development of centanafadine leading to this first approval for ADHD in adult and paediatric patients.
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Anthelminthic Agents
Drug Regulation